Regeneron Expands Libtayo Approval for High-Risk CSCC
Toronto, Ontario, Canada, August 8, 2026 Regeneron Canada Company announced that Health Canada has approved Libtayo® (cemiplimab for injection)...
Regeneron
Advertisement
Regeneron Highlights Phase 3 FOP and Metabolic Data
TARRYTOWN, N.Y., June 4, 2026 Regeneron Pharmaceuticals has unveiled a broad slate of new clinical and preclinical research across...
Regeneron’s Ebola Antibody Prioritized by WHO for Bundibugyo Outbreak Research
TARRYTOWN, N.Y. | May 28, 2026 Regeneron Pharmaceuticals announced that maftivimab, the lead neutralizing antibody within its FDA-approved Ebola...
Regeneron’s Lynozyfic Shows 100% Complete Responses in AL Amyloidosis Trial
TARRYTOWN, N.Y., May 21, 2026 Regeneron Pharmaceuticals announced highly encouraging early clinical data from the Phase 1/2 LINKER-AL2 trial...
Regeneron Pharmaceuticals Melanoma Trial Misses Primary PFS Goal
TARRYTOWN, New York, May 15, 2026 Regeneron Pharmaceuticals announced updated results from its Phase 3 melanoma trial evaluating the...
Advertisements
Regeneron Otarmeni Gene Therapy FDA Hearing Breakthrough
TARRYTOWN, N.Y., April 23, 2026 Regeneron Pharmaceuticals has achieved a landmark milestone as the U.S. Food and Drug Administration...
Regeneron & Sanofi Secure FDA Approval for Dupixent in Pediatric CSU
Tarrytown, New York, USA & Paris, France – April 22, 2026 In a significant advancement for pediatric immunology and...
Regeneron Cemdisiran Shows Strong gMG Phase 3 Results
Tarrytown, New York, USA – April 21, 2026 In a significant breakthrough for autoimmune neurology, Regeneron Pharmaceuticals has reported...
Telix and Regeneron Partner to Advance Radiopharma Therapies
Melbourne, Australia & Tarrytown, New York | April 13, 2026 Telix Pharmaceuticals and Regeneron Pharmaceuticals have announced a strategic...
Regeneron Dupixent EU Approval Expands Pediatric CSU Care
TARRYTOWN, N.Y. and PARIS, April 13, 2026 Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved...
Advertisement
